Prelude Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PRELUDE THERAPEUTICS INCORPORATED | ||
| Date: February 15, 2024 | By: | /s/ Krishna Vaddi |
|---|---|---|
| Krishna Vaddi, Ph.D | ||
| Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Krishna VaddiKrishna Vaddi, Ph.D. | Chief Executive Officer and Director(Principal Executive Officer) | February 15, 2024 |
| /s/ Laurent ChardonnetLaurent Chardonnet | Chief Financial Officer(Principal Accounting and Financial Officer) | February 15, 2024 |
| /s/ Paul A. Friedman | Chairman and Director | February 15, 2024 |
| Paul A. Friedman, M.D. | ||
| /s/ Martin Babler | Director | February 15, 2024 |
| Martin Babler | ||
| /s/ Julian Baker | Director | February 15, 2024 |
| Julian Baker | ||
| /s/ David Bonita | Director | February 15, 2024 |
| David Bonita, M.D. | ||
| /s/ Mardi C. Dier | Director | February 15, 2024 |
| Mardi C. Dier | ||
| /s/ Victor Sandor | Director | February 15, 2024 |
| Victor Sandor, M.D.C.M. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.